Staels B, Martin G, Martinez M, Albert C, Peinado-Onsurbe J, Saladin R, Hum D W, Reina M, Vilaro S, Auwerx J
U.325 INSERM, Département d'Athérosclérose, Institut Pasteur, 1 Rue Calmette, 59019 Lille, France.
J Biol Chem. 1996 Jul 19;271(29):17425-32. doi: 10.1074/jbc.271.29.17425.
Lipoprotein lipase (LPL), an enzyme which hydrolyzes triglycerides and participates in the catabolism of remnant lipoproteins, plays a crucial role in energy and lipid metabolism. The goal of this study was to analyze the expression and regulation of the LPL gene in human adrenals. Reverse transcriptase-polymerase chain reaction amplification and sequence analysis demonstrated the presence of LPL mRNA in fetal and adult human adrenal cortex. Furthermore, the human adrenocortical carcinoma cell line, NCI-H295, expresses LPL mRNA and protein, which is localized to the outer cellular membrane as demonstrated by immunofluorescence confocal microscopy and can be released in the medium by heparin addition. To asses whether the LPL gene is regulated by agents regulating adrenal steroidogenesis, NCI-H295 cells were treated with activators of second messenger systems. Whereas the calcium-ionophore A23187 did not affect LPL gene expression, treatment with phorbol 12-myristate 13-acetate decreased LPL mRNA levels in a time- and dose-dependent manner. This decrease after phorbol 12-myristate 13-acetate was associated with diminished heparin-releasable LPL mass and activity in the culture medium. Addition of the cAMP analog 8-Br-cAMP to NCI-H295 cells resulted in a rapid, but transient dose-dependent induction of LPL mRNA. Treatment with the protein synthesis inhibitor cycloheximide gradually induced, whereas simultaneous addition of cAMP and cycloheximide superinduced LPL mRNA levels. Nuclear run-on analysis indicated that the effects of cAMP and cycloheximide occurred at the transcriptional and post-transcriptional level, respectively. Transient co-transfection assays demonstrated that the first 230 base pairs of the proximal LPL promoter contain a cAMP-responsive element activated by protein kinase A and transcription factors belonging to the CREB/CREM family. These data indicate that LPL is expressed in human adrenal cortex and regulated in NCI-H295 adrenocortical carcinoma cells by activators of the protein kinase A and protein kinase C second messenger pathways in a manner comparable to P450scc, which catalyzes the first step in adrenal steroidogenesis. These observations suggest a role for LPL in adrenal energy and/or lipid metabolism and possibly in steroidogenesis.
脂蛋白脂肪酶(LPL)是一种水解甘油三酯并参与残余脂蛋白分解代谢的酶,在能量和脂质代谢中起关键作用。本研究的目的是分析LPL基因在人肾上腺中的表达和调控。逆转录聚合酶链反应扩增和序列分析表明,LPL mRNA存在于胎儿和成人肾上腺皮质中。此外,人肾上腺皮质癌细胞系NCI-H295表达LPL mRNA和蛋白,免疫荧光共聚焦显微镜显示其定位于细胞外膜,并且添加肝素后可释放到培养基中。为了评估LPL基因是否受调节肾上腺类固醇生成的因子调控,用第二信使系统激活剂处理NCI-H295细胞。钙离子载体A23187不影响LPL基因表达,而佛波醇12-肉豆蔻酸酯13-乙酸酯处理以时间和剂量依赖的方式降低LPL mRNA水平。佛波醇12-肉豆蔻酸酯13-乙酸酯处理后的这种降低与培养基中肝素可释放的LPL量和活性降低有关。向NCI-H295细胞中添加cAMP类似物8-Br-cAMP导致LPL mRNA快速但短暂的剂量依赖性诱导。用蛋白质合成抑制剂环己酰亚胺处理逐渐诱导,而同时添加cAMP和环己酰亚胺则超诱导LPL mRNA水平。核转录分析表明,cAMP和环己酰亚胺的作用分别发生在转录和转录后水平。瞬时共转染试验表明,LPL近端启动子的前230个碱基对包含一个由蛋白激酶A和属于CREB/CREM家族的转录因子激活的cAMP反应元件。这些数据表明,LPL在人肾上腺皮质中表达,并在NCI-H295肾上腺皮质癌细胞中受蛋白激酶A和蛋白激酶C第二信使途径激活剂的调控,其方式与催化肾上腺类固醇生成第一步的P450scc相似。这些观察结果提示LPL在肾上腺能量和/或脂质代谢以及可能在类固醇生成中起作用。